EstroTep 500 MBq/mL

DRUG3 trials

Sponsors

Institut Curie, Istituto Europeo Di Oncologia S.r.l., Centre Hospitalier Universitaire De Toulouse

Conditions

EndometriosisMetastatic hormone receptor-positive/HER2-negative breast cancerWomen with ER+ HER2- metastatic breast cancer who progressed on first line therapy with CDK4/6 inhibitor and aromatase inhibitor

Phase 2

Use of a new diagnostic tool in the detection and characterization of endometriosis lesions. ENDO-TEP

Not yet recruitingCTIS2025-520637-24-00

Centre Hospitalier Universitaire De ToulouseEndometriosis

Target: 20Updated: 2025-05-23

Elacestrant and exemestane for patients with pretreated HR+/HER2- metastatic breast cancer and [18F]-FES-avid lesions (COMBINE): a proof-of-concept phase 2 clinical trial

Not yet recruitingCTIS2024-519792-25-00

Istituto Europeo Di Oncologia S.r.l.Metastatic hormone receptor-positive/HER2-negative breast cancer

Target: 26Updated: 2025-10-10

Phase 3

"ECLECTIC": EstroTEP and circulating biomarkers to determine the optimal second line therapy for ER-positive HER2-negative metastatic breast cancer patients

RecruitingCTIS2023-506282-66-00

Institut CurieWomen with ER+ HER2- metastatic breast cancer who progressed on first line therapy with CDK4/6 inhibitor and aromatase inhibitor

Start: 2024-05-27Target: 300Updated: 2025-11-10